ProPhase Labs

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.

Earnings data Q4 2022

Earnings data Q1 2023

Presentation to be given in Collaboration with the Mayo Clinic   at the   United States and Canadian Academy of Pathology   (USCAP) Annual Meeting

ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test

Medical diagnostic and testing concern ProPhase Labs, Inc. gets put in the spotlight today. ProPhase Labs, Inc. has seen huge revenue growth from Covid testing but is rapidly diversifying into other areas.

ProPhase Labs: Lots Of Moving Pieces

GARDEN CITY, NY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. “ProPhase” (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it has entered into an asset purchase agreement to acquire from Stella Diagnostics, Inc. (“Stella”) world-wide exclusive rights to Stella's BE-Smart Esophageal Pre-Cancer diagnostic screening test and related intellectual property assets for approximately $4.5 million dollars, comprised of approximately $3.5 million in cash and $1 million in ProPhase common stock. Under the terms of the agreement, an additional $2 million of Company common stock may be issued to Stella in the future upon the achievement of a revenue-based commercial milestone within the five-year period following the closing. Stella will also receive a 5% royalty based on adjusted gross margin generated from the commercialization of the intellectual property acquired from Stella. The transaction is subject to approval by Stella shareholders and is expected to close in early January 2023. ThinkEquity acted as advisor to ProPhase Labs in the transaction.

ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test

GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022 at 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation.

ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022

Lantern Pharma

Fintel reports that ProPhase Labs, Inc. has filed a 13G form with the SEC disclosing ownership of 910,000 shares of Lantern Pharma Inc. (LTRN). This represents 8.4% of the company.

ProPhase Labs Discloses 8.4% Position in LTRN / Lantern Pharma After Q3 Results

ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2022 Earnings Conference Call November 10, 2022 11:00 AM ET Company Participants Ted Karkus – Chairman and Chief Executive Officer Conference Call Participants Fred McDonald – Private Investor Yi Chen – H.C. Wainwright Dennis Waldman – Barrett Productions, LLC Patrick Patterson – Investor Operator Good morning, afternoon, evening, and welcome to the ProPhase Labs Third Quarter 2022 Financial Results Conference Call.

ProPhase Labs, Inc. (PRPH) Q3 2022 Earnings Call Transcript

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -60% and 28.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Q3 Earnings Miss Estimates

GARDEN CITY, NY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participating in the Q4 Investor Summit Conference, which will take place on November 14, 2022 in New York, New York. ProPhase Labs' CEO and Chairman of the Board of Directors, Ted Karkus will be presenting at 3:00 PM ET on November 14, 2022.

ProPhase Labs to Present at Investor Summit Group's Q4 Conference

GARDEN CITY, NY, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, November 10, 2022 at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2022. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 at 11:00 a.m. Eastern Time

Assertio Therapeutics Inc

Verona Pharma

This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed's stance and volatile price swings that include declines of more than 20% in the major indexes are prompting investors to consider defensive investments.

3 Small-Cap Pharma Stocks For A 2022 Melt-Up

GARDEN CITY, NY, Oct. 18, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at The Mandarin Oriental Hotel in New York, New York.

ProPhase Labs to Present at The ThinkEquity Conference

GARDEN CITY, NY, Oct. 17, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth-oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, Nebula Genomics, Inc., has added Russ B. Altman, M.D., Ph.D to its Advisory Board. Dr. Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and Computer Science, and past chair of the Bioengineering Department at Stanford University. Dr. Altman is the second member of Nebula's Advisory Board and joins Dr. George Church, Nebula's Founder and Advisory Board Chairman. Nebula Genomics, a global leader in direct-to-consumer whole genome sequencing, has achieved significant year over year growth. Dr. Altman's expertise will support continued expansion through thought leadership, industry knowledge and strategic guidance.

Nebula Genomics Strengthens Advisory Board with Appointment of Russ Altman, M.D., Ph.D.

ProPhase Labs released record breaking Q2 2022 results beating earnings expectations by $0.22 with EPS of $0.40. ProPhase Labs has surpassed earning expectations for the last three consecutive quarters.

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

Ashford Hospitality Trust

BankFinancial

Consolidated Water

LogicBio Therapeutics Inc

A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation.

5 Big Winners as Dollar Strengthens on Fed Rate Hike

Here is how ProPhase Labs, Inc. (PRPH) and Concert Pharmaceuticals (CNCE) have performed compared to their sector so far this year.

Are Medical Stocks Lagging ProPhase Labs (PRPH) This Year?

GARDEN CITY, NY, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022 at 2:30 pm, Eastern Time. The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.

ProPhase Labs to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

Does ProPhase Labs, Inc. (PRPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why ProPhase Labs, Inc. (PRPH) is a Great Momentum Stock to Buy

ProPhase Labs, Inc (NASDAQ:PRPH ) Q2 2022 Earnings Conference Call August 11, 2022 9:00 AM ET Company Participants Ted Karkus - Chairman & Chief Executive Officer Conference Call Participants Yi Chen - H.C. Wainwright Dennis Waldman - Barrett Productions, LLC Operator Good morning, and welcome to the ProPhase Labs Second Quarter 2022 Financial Results and Corporate Update.

ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q2 2022 Results - Earnings Call Transcript

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 233.33% and 28.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Tops Q2 Earnings and Revenue Estimates

GARDEN CITY, NY, Aug. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, August 11, 2022 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30,2022. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 at 11:00 a.m. Eastern Time

ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in ProPhase Labs, Inc. (PRPH): Can Its 8% Jump Turn into More Strength?

ProPhase Labs has expanded its in-house testing capabilities for the diagnostics of the new clinical chemistry, immunoassay, hematology, hemostasis, and urinalysis analyzers. ProPhase Labs has successfully obtained rights to commercialize two patented small molecule PIM kinase inhibitors in the licensing agreement with Global BioLife, Inc.

ProPhase Labs: A Growth Stock At An Attractive Valuation

Garden City, NY, July 21, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it has granted an inducement stock option to purchase up to 250,000 shares of the Company's common stock to Dennis Grishin, who recently joined the Company as Chief Scientific Officer of ProPhase Precision Medicine, Inc. This award was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded under the Company's stockholder approved equity plan. The option award will vest as follows, contingent upon continued service: 50% is immediately vested, and the balance will vest in equal annual installments over the next two years. The options have an exercise price of $13.00 per share and will be exercisable for a period of 7 years.

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Confirms Quarterly Growth continues year-over-year

ProPhase Labs Announces Licensing of New Investigational Cancer Compounds

Chefs' Warehouse

Daqo New Energy

Franklin Covey

USA Truck

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are USAK, FC, PRPH, DQ and CHEF.

News for ProPhase Labs Stock (PRPH)